505(b)(1)
LXP103
LXP103 has obtained patents in seven countries. Animal studies suggest that LXPA103, when combined with Osimertinib for non-small cell lung cancer, delays resistance to the treatment. Preclinical studies and new formulations are currently underway.
适应症
Non-Small Cell Lung Cancer & Alzheimer's disease
开发价值
Animal test results suggest that LXP103 is more effective when used in combination with Osimertinib, the current third-generation treatment for EGFR-mutated non-small cell lung cancer.
临床试验
最新进度
临床前
申请
第一阶段
第二阶段
第三阶段
上市
临床前
专利
已取得台美之专利，其他地区专利申请中
- Taiwan
- United States